ES2354103A1 - Capillary composition activator of the sirtuinas and use of the sirtuinas. (Machine-translation by Google Translate, not legally binding) - Google Patents
Capillary composition activator of the sirtuinas and use of the sirtuinas. (Machine-translation by Google Translate, not legally binding) Download PDFInfo
- Publication number
- ES2354103A1 ES2354103A1 ES201031963A ES201031963A ES2354103A1 ES 2354103 A1 ES2354103 A1 ES 2354103A1 ES 201031963 A ES201031963 A ES 201031963A ES 201031963 A ES201031963 A ES 201031963A ES 2354103 A1 ES2354103 A1 ES 2354103A1
- Authority
- ES
- Spain
- Prior art keywords
- hair
- composition according
- extract
- capillary
- weight ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 239000012190 activator Substances 0.000 title 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 25
- 230000003698 anagen phase Effects 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 20
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 19
- 229940016667 resveratrol Drugs 0.000 claims abstract description 19
- 230000003213 activating effect Effects 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 240000006365 Vitis vinifera Species 0.000 claims abstract description 9
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 9
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 9
- 239000002453 shampoo Substances 0.000 claims abstract description 8
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 6
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940054264 alaria esculenta extract Drugs 0.000 claims abstract description 6
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 6
- 229960000367 inositol Drugs 0.000 claims abstract description 6
- 239000006210 lotion Substances 0.000 claims abstract description 6
- 229940101267 panthenol Drugs 0.000 claims abstract description 6
- 235000020957 pantothenol Nutrition 0.000 claims abstract description 6
- 239000011619 pantothenol Substances 0.000 claims abstract description 6
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 6
- 241000195493 Cryptophyta Species 0.000 claims abstract description 5
- 102000004127 Cytokines Human genes 0.000 claims abstract description 5
- 108090000695 Cytokines Proteins 0.000 claims abstract description 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 5
- 241001466453 Laminaria Species 0.000 claims abstract description 5
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims abstract description 5
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract 3
- 244000182633 Cinchona succirubra Species 0.000 claims abstract 3
- 235000006768 Cinchona succirubra Nutrition 0.000 claims abstract 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract 3
- 102000014171 Milk Proteins Human genes 0.000 claims abstract 3
- 108010011756 Milk Proteins Proteins 0.000 claims abstract 3
- 229940105017 achillea millefolium extract Drugs 0.000 claims abstract 3
- 229960001375 lactose Drugs 0.000 claims abstract 3
- 239000008101 lactose Substances 0.000 claims abstract 3
- 235000021239 milk protein Nutrition 0.000 claims abstract 3
- 229940061630 tussilago farfara extract Drugs 0.000 claims abstract 3
- 210000004209 hair Anatomy 0.000 claims description 87
- 239000002904 solvent Substances 0.000 claims description 11
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 239000003352 sequestering agent Substances 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 5
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 4
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002304 perfume Substances 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 235000010384 tocopherol Nutrition 0.000 claims description 4
- 239000011732 tocopherol Substances 0.000 claims description 4
- 229960001295 tocopherol Drugs 0.000 claims description 4
- 229930003799 tocopherol Natural products 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 claims description 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 239000002280 amphoteric surfactant Substances 0.000 claims description 3
- 239000003945 anionic surfactant Substances 0.000 claims description 3
- 229920013750 conditioning polymer Polymers 0.000 claims description 3
- YCIMNLLNPGFGHC-UHFFFAOYSA-N o-dihydroxy-benzene Natural products OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 3
- 229940023735 panthenyl ethyl ether Drugs 0.000 claims description 3
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 3
- 229960001755 resorcinol Drugs 0.000 claims description 3
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims description 2
- 208000024963 hair loss Diseases 0.000 claims description 2
- 230000003676 hair loss Effects 0.000 claims description 2
- 239000003605 opacifier Substances 0.000 claims description 2
- 235000018991 trans-resveratrol Nutrition 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims 3
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- 108050002485 Sirtuin Proteins 0.000 abstract description 12
- 102000011990 Sirtuin Human genes 0.000 abstract description 12
- -1 pantenyl ethyl ether Chemical compound 0.000 abstract description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 1
- 210000004761 scalp Anatomy 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 230000003797 telogen phase Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 230000031774 hair cycle Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229930192334 Auxin Natural products 0.000 description 3
- 108010041191 Sirtuin 1 Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003644 anagen/telogen ratio Effects 0.000 description 3
- 239000002363 auxin Substances 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000000344 Sirtuin 1 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- 241000199897 Alaria esculenta Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 235000021513 Cinchona Nutrition 0.000 description 1
- 241000157855 Cinchona Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000218228 Humulus Species 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- QACUPNAKIPYZAW-RMQWDSPGSA-N O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O QACUPNAKIPYZAW-RMQWDSPGSA-N 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241001460982 Tricogena Species 0.000 description 1
- 240000000377 Tussilago farfara Species 0.000 description 1
- 235000004869 Tussilago farfara Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 150000001579 beta-carotenes Chemical class 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- CZMOVKLQUFOJAZ-UHFFFAOYSA-N butyl n-(3-iodoprop-1-ynyl)carbamate Chemical compound CCCCOC(=O)NC#CCI CZMOVKLQUFOJAZ-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 235000020934 caloric restriction Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 230000006003 cornification Effects 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000009646 cyclic growth Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940047642 disodium cocoamphodiacetate Drugs 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940082519 peg-4 rapeseedamide Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000500 vasculoprotective effect Effects 0.000 description 1
- 230000001643 venotonic effect Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Composición capilar activadora de las sirtuinas y utilización de la misma.Activating hair composition of sirtuins and use of it.
La presente invención se refiere a una composición capilar activadora de las sirtuinas y a la utilización de la misma. Más en particular, la presente invención se refiere a una composición capilar que es capaz de activar la SIRT1, "sirtuina-1 deacetilasa dependiente de NAD", una proteína codificada por el gen "SIRT1", que regula la actividad de varios factores de transcripción y de enzimas sensibles a la disponibilidad de nutrientes, así como a su utilización.The present invention relates to a capillary composition activating the sirtuins and use Of the same. More particularly, the present invention relates to a hair composition that is capable of activating SIRT1, "NAD-dependent sirtuin-1 deacetylase", a protein encoded by the "SIRT1" gene, which regulates the activity of various transcription factors and sensitive enzymes to the availability of nutrients, as well as their use.
La composición capilar de la invención permite prolongar en el tiempo la fase anágena o de crecimiento del cabello gracias a una mezcla de principios activos que incluye, entre otros, un componente de resveratrol (5-[(E)-2-(4-hidroxifenil)etenil]benzeno-1,3-diol) y/u oligómeros del mismo, procedente de extracto de Vitis vinifera.The hair composition of the invention makes it possible to prolong the anagen or hair growth phase over time thanks to a mixture of active ingredients that includes, among others, a resveratrol component (5 - [(E) -2- (4-hydroxyphenyl) ) ethenyl] benzene-1,3-diol) and / or oligomers thereof, from Vitis vinifera extract.
Son conocidos en el estado de la técnica numerosas composiciones que contienen resveratrol. Por ejemplo, la WO2006/087759, "Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field", reivindica una composición farmacéutica que comprende resveratrol y/o raíz de Polygonum cuspidatum y curcumina y/o raíz de Curcuma longa, como principios activos en asociación con uno o más adyuvantes y/o excipientes farmacéuticamente aceptables. Esta composición se emplea para el tratamiento del cáncer, de enfermedades de la piel, para tratar o prevenir el envejecimiento y para el tratamiento y la profilaxis de enfermedades del sistema pilífero en base a la acción antiinflamatoria y antineoplásica del resveratrol y la curcumina como mezcla antioxidante.Numerous compositions containing resveratrol are known in the state of the art. For example, WO2006 / 087759, "Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field", claims a pharmaceutical composition comprising resveratrol and / or root of Polygonum cuspidatum and curcumin and / or root of Curcuma longa , as active ingredients in association with one or more pharmaceutically acceptable adjuvants and / or excipients. This composition is used for the treatment of cancer, skin diseases, to treat or prevent aging and for the treatment and prophylaxis of diseases of the pyloric system based on the anti-inflammatory and antineoplastic action of resveratrol and curcumin as an antioxidant mixture .
Igualmente, la ES 2 209 187 T3, "Compuestos a base de derivados de resveratrol", describe compuestos de resveratrol estables frente al aire y la luz y la utilización de los mismos como fotoprotectores solares, como productos dietéticos o como medicamentos venotónicos y vasculoprotectores en base a sus propiedades antioxidantes y antiinflamatorias.Similarly, ES 2 209 187 T3, "Compounds to base of resveratrol derivatives, "describes compounds of Resveratrol stable against air and light and the use of themselves as solar photoprotectors, as dietary products or as venotonic and vasculoprotective medications based on their antioxidant and anti-inflammatory properties.
También en los últimos años han aparecido en el mercado muy numerosos productos dietéticos y cosméticos que incluyen resveratrol entre sus principios activos, en particular por su acción antiinflamatoria, antienvejecimiento o como mimético de la restricción calórica.Also in recent years they have appeared in the market very numerous dietary and cosmetic products that include resveratrol among its active ingredients, in particular for its anti-inflammatory, anti-aging or mimetic action of the caloric restriction
Sin embargo, en ninguno de los documentos o productos comerciales pertenecientes al estado de la técnica se describe una composición capilar activadora de las sirtuinas que permita prolongar en el tiempo la fase anágena o de crecimiento del cabello gracias a una mezcla de principios activos que incluye, entre otros, un componente de resveratrol (5-[(E)-2-(4-hidroxifenil)etenil]benzeno-1,3-diol) y/u oligómeros del mismo, procedente de extracto de Vitis vinifera.However, none of the documents or commercial products belonging to the state of the art describe a capillary composition activating the sirtuins that allows the anagen or hair growth phase to be prolonged in time thanks to a mixture of active ingredients that includes, among others, a component of resveratrol (5 - [(E) -2- (4-hydroxyphenyl) ethenyl] benzene-1,3-diol) and / or oligomers thereof, derived from Vitis vinifera extract.
Así, el objeto de la presente invención es una composición capilar activadora de las sirtuinas que permite prolongar en el tiempo la fase anágena o de crecimiento del cabello gracias a una mezcla de principios activos que incluye, entre otros, un componente de resveratrol (5-[(E)-2-(4-hidroxifenil)-etenil]benzeno-1,3-diol) y/u oligómeros del mismo, procedente de extracto de Vitis vinifera. La composición activadora de las sirtuinas de la presente invención incluye otros componentes, tales como citoquinas lácteas, inositol, acetil cisteína y acetil metionina, auxina tricogena, extracto de alga laminaria, extracto de Alaria esculenta y pantenol, además de disolventes, antioxidantes y aditivos adecuados para su formulación.Thus, the object of the present invention is a hair activating composition of the sirtuins that allows the anagen or hair growth phase to be prolonged over time thanks to a mixture of active ingredients that includes, among others, a resveratrol component (5- [(E) -2- (4-hydroxyphenyl) -etenyl] benzene-1,3-diol) and / or oligomers thereof, from Vitis vinifera extract. The activating composition of the sirtuins of the present invention includes other components, such as milk cytokines, inositol, acetyl cysteine and acetyl methionine, trichogenic auxin, laminaria algae extract, Alaria esculenta extract and panthenol, in addition to suitable solvents, antioxidants and additives For its formulation.
El pelo tiene un crecimiento cíclico denominado ciclo piloso, poseyendo cada folículo su propio ciclo independientemente de los que haya a su alrededor. Básicamente, las fases del ciclo piloso son:The hair has a cyclic growth called hair cycle, each follicle having its own cycle regardless of those around you. Basically, the phases of the hair cycle are:
Fase anágena: durante la cual el pelo está pegado a la papila, nace y crece. Se extiende durante una media de tres años. La forma del folículo en esta fase es similar a la de una cebolla, más ancha en la base que en el tallo. El pelo crece sin cesar debido a que las células de la matriz del folículo se dividen por mitosis constantemente.Anagen phase: during which the hair is stuck to the papilla, it is born and grows. It extends for an average of three years. The shape of the follicle in this phase is similar to that of a onion, wider at the base than on the stem. The hair grows without cease because the follicle matrix cells divide by mitosis constantly.
Fase catágena: Es una fase de transición. Se extiende unas 3 semanas, durante los cuales el crecimiento se detiene y se separa de la papila, cesando la actividad de las células de la matriz, incluido los melanocitos. El bulbo toma un aspecto cilíndrico.Catagen phase: It is a transition phase. Be extends about 3 weeks, during which the growth is stops and separates from the papilla, ceasing the activity of the matrix cells, including melanocytes. The bulb takes a cylindrical appearance.
Fase Telógena: Es la fase de descanso y de caída del pelo, dura unos 3 meses. La raíz del pelo toma un aspecto de cerilla y permanece insertado en el folículo.Telogen Phase: It is the rest and fall phase of hair, lasts about 3 months. The hair root takes on an aspect of match and remains inserted in the follicle.
Así, cuando el pelo termina de crecer en la fase anágena, la reproducción de las células indiferenciadas de la base del folículo también se detiene, la raíz se hace progresivamente más estrecha y las células que se encuentran encima de la papila sufren un proceso de cornificación. Finalmente, la raíz se separa de la papila del pelo y éste se cae. Antes de que se desprenda, se inicia la formación de un nuevo pelo en la base del folículo.Thus, when the hair finishes growing in the phase anagen, the reproduction of undifferentiated base cells of the follicle also stops, the root becomes progressively more narrow and the cells that are on top of the papilla suffer a cornification process. Finally, the root separates from the hair papilla and it falls out. Before it comes off, it starts the formation of a new hair at the base of the follicle.
La composición capilar de la invención
incluyendo resveratrol y otros componentes activos es capaz de
estimular la acción de las sirtuinas, proteínas íntimamente
relacionadas con la supervivencia celular, que actúan regulando la
actividad de otros genes relacionados con las defensas celulares, la
actividad neuronal, la reparación de daños, la producción de energía
y la muerte celular programada. La activación de las sirtuinas
reequilibra el ciclo piloso excesivamente acelerado, preservando así
el capital capilar. El resveratrol provoca que las mitocondrias
aumenten su respiración, consumiendo una mayor cantidad de oxígeno,
lo que produce NAD y elimina NADH, que a su vez es inhibidor de
estas sirtuinas. Estudios recientes han demostrado que el
resveratrol induce un cambio importante en el metabolismo aumentando
la eficacia de extracción bioenergética a través de un incremento en
la cantidad de mitocondrias, los orgánulos responsables en los
organismos de la mayor parte de la síntesis de ATP (Plácido Navas y
Guillermo López-Lluch, Centro Andaluz de Biología
del Desarrollo, Universidad Pablo de
Olavide-CSIC,
Sevilla).The capillary composition of the invention including resveratrol and other active components is capable of stimulating the action of sirtuins, proteins intimately related to cell survival, which act by regulating the activity of other genes related to cellular defenses, neuronal activity, repair of damage, energy production and programmed cell death. The activation of the sirtuins rebalances the excessively accelerated hair cycle, thus preserving the capillary capital. Resveratrol causes mitochondria to increase their breathing, consuming a greater amount of oxygen, which produces NAD and eliminates NADH, which in turn is an inhibitor of these sirtuins. Recent studies have shown that resveratrol induces a significant change in metabolism by increasing the efficiency of bioenergetic extraction through an increase in the amount of mitochondria, the organelles responsible in the organisms for most of the synthesis of ATP (Placido Navas and Guillermo López-Lluch, Andalusian Center for Development Biology, Universidad Pablo de Olavide-CSIC,
Seville).
La composición capilar activadora de las sirtuinas de la presente invención incluye como componentes activos, entre otros, un componente de resveratrol (5-[(E)-2-(4-hidroxifenil)-etenil]benzeno-1,3-diol) y/u oligómeros del mismo, procedente de extracto de Vitis vinifera, citoquinas lácteas, inositol, acetil cisteína y acetil metionina, auxina tricogena, extracto de alga laminaria, extracto de Alaria esculenta y pantenol, además de disolventes, antioxidantes y aditivos adecuados para su formulación.The capillary activating composition of the sirtuins of the present invention includes as active components, among others, a resveratrol component (5 - [(E) -2- (4-hydroxyphenyl) -ethenyl] benzene-1,3-diol) and / u oligomers thereof, from Vitis vinifera extract, milk cytokines, inositol, acetyl cysteine and acetyl methionine, trichogenic auxin, laminaria algae extract, Alaria esculenta extract and panthenol, in addition to solvents, antioxidants and suitable additives for its formulation .
En una forma de realización preferente, la composición capilar activadora de las sirtuinas de la presente invención incluye los siguientes componentes activos en los porcentajes (en peso) indicados:In a preferred embodiment, the hair composition activating the sirtuins of the present invention includes the following active components in the percentages (by weight) indicated:
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
En una forma de realización de la invención, la proporción de Extracto de Vitis vinifera vine presente en la composición es equivalente a aproximadamente un 0,002 - 0,02% de una mezcla de resveratrol y sus oligómeros (Resveratrox®), proporcionando un porcentaje de trans-resveratrol de aproximadamente un 0,0002 - 0,002%.In one embodiment of the invention, the proportion of Vitis vinifera Vine Extract present in the composition is equivalent to approximately 0.002-0.02% of a mixture of resveratrol and its oligomers (Resveratrox®), providing a percentage of trans -resveratrol of approximately 0.0002 - 0.002%.
\newpage\ newpage
La acción conjunta del resveratrol y el resto de los componentes activos citados anteriormente permite prolongar la fase anágena del ciclo piloso tal como se explica más detalladamente en los ejemplos.The joint action of resveratrol and the rest of the active components mentioned above allow to prolong the anagen phase of the hair cycle as explained in more detail In the examples.
Por su parte, las citoquinas presentes en las proteínas lácteas-lactosa actúan como mensajeras y promotoras de la fase anágena evitando la aparición de factores de destrucción celular, y junto con el inositol, permite a las células responder a los mensajes del entorno, en especial con referencia a agentes ambientales que provocan estrés oxidativo y desequilibrios en la respiración celular. Ambos componentes facilitan así la actuación del resveratrol incluido en la composición de la invención. De igual forma, la cisteína y la metionina en su forma acetilada, aminoácidos azufrados componentes de la queratina, estimulan el crecimiento y mejoran el tallo capilar.On the other hand, the cytokines present in the lactose-lactose proteins act as messengers and promoters of the anagen phase avoiding the appearance of factors of cell destruction, and together with inositol, allows cells respond to messages from the environment, especially with reference to environmental agents that cause oxidative stress and imbalances in cellular respiration Both components thus facilitate performance of resveratrol included in the composition of the invention. Similarly, cysteine and methionine in its form acetylated, sulfur amino acids keratin components, They stimulate growth and improve the hair shaft.
Los extractos de Aquilea millefolium, Tussilago farfara y Cinchona cuccirubra, por ejemplo contenidos en una mezcla de natural tal como Auxina tricogena, suplementa la acción de los componentes anteriormente citados mejorando la calidad del cabello, activando la respiración de las células capilares y equilibrando los procesos de oxidación-reducción en las mismas.Extracts of Aquilea millefolium , Tussilago farfara and Cinchona cuccirubra , for example contained in a mixture of natural such as Tricogena Auxin , supplements the action of the aforementioned components, improving hair quality, activating hair cell respiration and balancing processes of oxidation-reduction in them.
La composición capilar de la invención se
complementa con principios activos procedentes de extractos de algas
laminarias con capacidad inhibidora de la
5-alfa-reductasa y, por tanto,
mejorando la acción antiinflamatoria y antigrasa de la composición
de la invención; así como con extracto de Alaria esculenta de
alto contenido en aminoácidos, en particular alanina, que rellena el
cabello dándole cuerpo, suavidad, facilita el peinado y evita el
encrespado. Este extracto de Alaria esculenta junto con el
pantenol y el pantenil etil éter incluidos en la composición de la
invención permiten que ésta tenga también un efecto acondicionador
de hidratación y reparación, mejorando así el tallo
capilar.The capillary composition of the invention is complemented with active ingredients derived from laminar seaweed extracts with 5-alpha-reductase inhibitory capacity and, therefore, improving the anti-inflammatory and anti-fat action of the composition of the invention; as well as with Alaria esculenta extract high in amino acids, in particular alanine, which fills the hair giving it body, softness, facilitates combing and prevents frizz. This extract of Alaria esculenta together with the panthenol and the panthenyl ethyl ether included in the composition of the invention also allow it to have a conditioning and hydration conditioning effect, thus improving the stem.
capillary.
Opcionalmente, la composición capilar de la invención puede contener otros ingredientes activos, tales como Rosmarinus officinalis o Humulus lupus.Optionally, the hair composition of the invention may contain other active ingredients, such as Rosmarinus officinalis or Humulus lupus .
En una forma de realización preferente de la composición de la invención, ésta se complementa con ingredientes con capacidad antioxidante. Entre los ingredientes antioxidantes se pueden citar, por ejemplo, ácido ascórbico, palmitato de ascorbilo, tocoferol, ascorbato sódico, beta-carotenos, flavonoides, BHT o BHA. Más particularmente ácido ascórbico, palmitato de ascorbilo y tocoferol en las proporciones en peso siguientes, con respecto a 100 g de la composición capilar:In a preferred embodiment of the composition of the invention, this is complemented with ingredients With antioxidant capacity. Among the antioxidant ingredients are They may cite, for example, ascorbic acid, ascorbyl palmitate, tocopherol, sodium ascorbate, beta-carotenes, flavonoids, BHT or BHA. More particularly ascorbic acid, ascorbyl palmitate and tocopherol in proportions by weight following, with respect to 100 g of the hair composition:
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
La composición capilar de la invención se puede obtener mediante los procesos habituales conocidos por el experto en la materia para su formulación en forma de, por ejemplo, loción capilar o champú. Para ello, la composición de la invención incluye distintos ingredientes adicionales tales como disolventes, conservantes, agentes secuestrantes, solubilizantes, agentes de ajuste del pH, perfumes, agentes tensioactivos, acondicionadores, agentes quelantes, opacificantes, antioxidantes, etc.The capillary composition of the invention can be obtain by the usual processes known to the expert in the matter for its formulation in the form of, for example, lotion hair or shampoo For this, the composition of the invention includes various additional ingredients such as solvents, preservatives, sequestering agents, solubilizers, agents pH adjustment, perfumes, surfactants, conditioners, chelating agents, opacifiers, antioxidants, etc.
Entre los agentes los agentes tensioactivos se pueden citar, por ejemplo, agentes tensioactivos aniónicos tales como Sodium Lauryl Sulfate, Sodium Laureth Sulfate, Disodium Laureth Sulfate; agentes tensioactivos anfóteros tales como Disodium Cocoamphodiacetate, Cocamidopropyl Betaine; agentes tensioactivos no iónicos tales como Cocamide DEA, Cocamide MEA, PEG-4 Rapeseedamide. Entre los polímeros acondicionadores se pueden citar, por ejemplo, Polyquaternium-7, Polyquaternium-22, PEG-15 Cocopolyamine. Ejemplos de agentes secuestrantes son Disodium EDTA, EDTA, DTPA. Entre los conservantes se pueden citar, por ejemplo, metilparaben, iodopropinil butilcarbamato, DMDM hidantoína, metilcloroisotiazolinona, metilisotiazolinona. Entre los agentes de ajuste del pH se pueden citar, por ejemplo, ácido láctico, ácido cítrico, NaOH, AMP. Ejemplos de agentes opacificantes son copolímeros estireno/VP, copolímeros estireno/acrilato. Como ejemplos de agentes reguladores de la viscosidad se mencionan cloruro sodio, cloruro de magnesio. Ejemplos de solubilizantes son PEG-40 - castor oil, PEG-60 Hydrogenated castor oil, laureth-9.Among the agents the surfactants are may cite, for example, anionic surfactants such as Sodium Lauryl Sulfate, Sodium Laureth Sulfate, Disodium Laureth Sulfate; amphoteric surfactants such as Disodium Cocoamphodiacetate, Cocamidopropyl Betaine; non surfactants ionics such as Cocamide DEA, Cocamide MEA, PEG-4 Rapeseedamide Among the conditioning polymers may be mentioned, for example, Polyquaternium-7, Polyquaternium-22, PEG-15 Cocopolyamine Examples of sequestering agents are Disodium EDTA, EDTA, DTPA. Among the preservatives can be mentioned, for example, methylparaben, iodopropinyl butylcarbamate, DMDM hydantoin, methylchloroisothiazolinone, methylisothiazolinone. Among the agents of pH adjustment can be cited, for example, lactic acid, acid Citrus, NaOH, AMP. Examples of opacifying agents are styrene / VP copolymers, styrene / acrylate copolymers. How Examples of viscosity regulating agents are mentioned sodium chloride, magnesium chloride. Examples of solubilizers are PEG-40 - castor oil, PEG-60 Hydrogenated castor oil, laureth-9.
\newpage\ newpage
En una realización preferente de la composición capilar de la invención en forma de loción, ésta incluye los siguientes ingredientes adicionales:In a preferred embodiment of the composition capillary of the invention in the form of lotion, this includes the following additional ingredients:
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
En una realización de la composición de la invención en forma de champú, ésta incluye los siguientes ingredientes adicionales:In an embodiment of the composition of the invention in the form of shampoo, this includes the following additional ingredients:
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Se llevó a cabo un estudio in vivo con 25
voluntarios humanos sanos a los que se les suministró la composición
capilar de la invención en forma de champú y de ampollas monodosis
para su utilización habitual durante 180
días.An in vivo study was carried out with 25 healthy human volunteers who were given the hair composition of the invention in the form of shampoo and single dose ampoules for routine use during 180
days.
Se escogieron para ello voluntarios sanos con una relación Anágeno/Telógeno < 4 (Varones: grados II-IV de Hamilton; mujeres: grados I-II de Ludwig) y que no se hubieran sometido a un tratamiento capilar previo durante los 3 meses anteriores al estudio, sin patologías del cuero cabelludo y que no estuvieran sometidos a un tratamiento previo con medicamentos que pudieran provocar alopecia ni fueran consumidores habituales de nutricosméticos. El objeto del estudio era evaluar la relación entre la fase anágena y telógena del cabello de los voluntarios, así como el aspecto general del cabello, el aspecto detallado del cuero cabelludo, el número de cabellos desprendidos durante el peinado (test "Combing") y el número de cabellos desprendidos durante el lavado (test "Washing").Healthy volunteers were chosen for it with An Anagen / Telogen ratio <4 (Men: degrees Hamilton II-IV; women: grades Ludwig I-II) and who would not have undergone a previous hair treatment during the 3 months prior to study, without scalp pathologies and that were not undergoing prior treatment with medications that could cause alopecia or were habitual consumers of Nutricosmetics The purpose of the study was to evaluate the relationship between the anagen and telogen phase of the hair of the volunteers, as well as the general appearance of the hair, the detailed appearance of the leather scalp, the number of hair detached during styling ("Combing" test) and the number of hair shed during washing ("Washing" test).
Antes de iniciar el estudio se pidió a los voluntarios que no se lavaran el cabello en las 48 h anteriores al primer control inicial ni se peinaran en las 24 h previas a esta visita T0). Durante la primera visita de control, se realizaron fotografías generales del cuero cabelludo, microfotografías del cuero cabelludo, tricogramas iniciales, ensayos de peinado y lavado del cabello de cada voluntario. Se pidió a los voluntarios que se lavaran el cabello con el champú conteniendo la composición de la invención a días alternos y que se aplicaran un vial monodosis conteniendo la composición de la invención en el cuero cabelludo a diario. Los voluntarios no emplearon ningún otro producto de tratamiento sobre el cuero cabelludo durante el período de realización del estudio.Before starting the study, the volunteers who will not wash their hair in the 48 hours prior to First initial check or comb in the 24 hours prior to this visit T0). During the first control visit, they were made general photographs of the scalp, photomicrographs of the scalp, initial tricograms, styling and washing tests of the hair of each volunteer. Volunteers were asked to wash the hair with the shampoo containing the composition of the invention on alternate days and that a single dose vial should be applied containing the composition of the invention in the scalp a diary. The volunteers did not use any other product of scalp treatment during the period of study completion
En las visitas de control T0 y T180 se realizan varias fotografías de la parte superior de la cabeza con el fin de comprobar si el tratamiento en estudio consigue mejorar el aspecto general del cabello a simple vista.In the T0 and T180 control visits are made several photographs of the top of the head in order to check if the treatment under study improves the appearance General hair at a glance.
La microcámara (TrichoScan®) es un equipo de diagnóstico profesional para la exploración de la piel. Su función es permitir la visión directa ampliada de una zona del cuero cabelludo, para la observación de los cabellos existentes y del estado en que se encuentran. Por comparación de las imágenes a T0 y T180 se puede observar si hay aumento del número de cabellos así como el grosor de los mismos. Las imágenes obtenidas al inicio y al final del estudio permiten valorar la eficacia del tratamiento (Figura 1).The microcamera (TrichoScan®) is a device of Professional diagnosis for skin examination. Its function is to allow expanded direct vision of an area of the leather scalp, for the observation of existing hair and state they are in By comparison of the images at T0 and T180 can be seen if there is an increase in the number of hair like this as the thickness of them. The images obtained at the beginning and at end of the study allow to assess the effectiveness of the treatment (Figure 1).
Consiste en la extracción por tracción de un número determinado de cabellos del cuero cabelludo con objeto de conocer en qué fase del ciclo de crecimiento piloso se hallan así como el aspecto inicial y final de los bulbos pilosos. El tricograma es una "instantánea" del estado de las raíces o bulbos pilosos y, por tanto, del cuero cabelludo en un determinado momento (Figura 2). En función de los resultados, permite conocer si el cabello se renueva normalmente o si existe alguna alteración de los ciclos capilares. En este estudio, se pretende averiguar si el tratamiento con la composición descrita en la presenta invención es capaz de mejorar el tricograma inicial del cuero cabelludo y si produce una mejora en la fisiología de los bulbos y las vainas capilares. Para ello se realiza al inicio (T0) y al final del estudio (T180). Como condición previa, cada voluntario no se habrá lavado ni tratado el cabello con ningún producto cosmético al menos las 48 h previas a la realización del tricograma, para mantener los cabellos que están próximos al final de la fase telógena y evitar la reducción artificial del porcentaje de pelos telogénicos observados en el tricograma. Se selecciona la zona parieto-occipital izquierda para realizar la toma de cabellos. Se colocan unas pinzas pean en la parte más próxima a la piel del cuero cabelludo y se tracciona en el sentido del crecimiento del pelo. El proceso de tracción se repite tantas veces como sea necesario hasta conseguir el número de cabellos necesario para el tricograma -entre 15 y 25 aprox. Inmediatamente después de la epilación, los bulbos pilosos se montan sobre portas de cristal con las raíces paralelas unas a otras, se fijan con Bálsamo de Canadá como medio transparentador para microscopía y se sitúa encima un cubreobjetos, quedando listas para el estudio microscópico. De esta manera se calcula:It consists of tensile extraction of a determined number of scalp hair in order to know at what stage of the hair growth cycle they are like this as the initial and final appearance of hair bulbs. The tricogram It is a "snapshot" of the state of the roots or hair bulbs and, therefore, of the scalp at a certain time (Figure 2). Depending on the results, lets know if the hair is renew normally or if there is any alteration of the cycles capillaries In this study, we try to find out if the treatment with the composition described in the present invention is capable of improve the initial tricogram of the scalp and if it produces a improvement in the physiology of the bulbs and hair sheaths. For This is done at the beginning (T0) and at the end of the study (T180). How precondition, each volunteer will not have washed or treated the hair with no cosmetic product at least 48 hours prior to realization of the tricogram, to keep the hair that are near the end of the telogen phase and avoid reduction artificial percentage of telogenic hairs observed in the tricogram The parieto-occipital zone is selected left to make hair taking. Tweezers are placed pean in the part closest to the skin of the scalp and it tracts in the direction of hair growth. The process of traction is repeated as many times as necessary until you get the number of hair needed for the tricogram - between 15 and 25 approx. Immediately after epilation, hair bulbs will mounted on glass slides with the roots parallel to each other others, are fixed with Canada Balm as a transparent medium for microscopy and a coverslip is placed, being ready for microscopic study. This way it is calculated:
- A0A0
- número de cabellos en fase anágena a T0 (antes del tratamiento)number of hair in anagen phase at T0 (before treatment)
- T0T0
- número de cabellos en fase telógena a T0 (antes del tratamiento)number of hair in telogen phase at T0 (before treatment)
- %A0% A0
- porcentaje de cabellos en fase anágena a T0percentage of hair in anagen phase a T0
- %T0% T0
- porcentaje de cabellos en fase telógena a T0percentage of hair in telogen phase a T0
- A0/T0A0 / T0
- relación entre cabellos en fase anágena y en fase telógena a T0relationship between hair in anagen phase and in phase telogenous to T0
- A180A180
- número de cabellos en fase anágena a T180number of hair in anagen phase a T180
- T180T180
- número de cabellos en fase telógena a T180number of hair in telogen phase a T180
- %A180% A180
- porcentaje de cabellos en fase anágena a T180percentage of hair in anagen phase a T180
- %T180% T180
- porcentaje de cabellos en fase telógena a T180percentage of hair in telogen phase a T180
- A180/T180A180 / T180
- relación entre cabellos en fase anágena y en fase telógena a T180relationship between hair in anagen phase and in phase telogen to T180
y se evalúan los resultados tomando como referencia los valores de tricograma considerados como "normales" en la bibliografía consultada. A modo de ejemplo, el estudio de eficacia del activo Prodhyhair concentré®, de Laboratoires Prod'Hyg, acepta como "normal" un valor de relación anágena/telógena superior o igual a 4. En consecuencia, en este estudio se considerará que la relación anágena/telógena es normal si A/T \geq 4.and the results are evaluated taking as reference the tricogram values considered as "normal" in the bibliography consulted. As an example, the efficacy study of the Prodhyhair concentré® asset, of Laboratoires Prod'Hyg, accepts as "normal" a value of anagen / telogen ratio greater than or equal to 4. Consequently, in This study will be considered that the anagen / telogen ratio is normal if A / T \ geq 4.
Se determina el número de cabellos que se desprenden durante el peinado del cabello en condiciones estandarizadas (Test "combing"). Se pretende que, tras el tratamiento con la composición descrita en la presente invención, el número de cabellos desprendidos durante el peinado sea inferior al inicial. Para ello se realizan los ensayos al inicio (T0), a mitad (T90) y al final del estudio (T180). Como condición previa, los voluntarios acuden al control sin haber lavado el cabello al menos en las 48 h previas y sin haberse peinado el cabello en las 24 h anteriores, con el objeto de mantener los cabellos que están próximos al final de la fase telógena y evitar la reducción artificial del porcentaje de pelos en fase telógena. Tras peinar 30 veces el cuero cabelludo de cada voluntario, los cabellos desprendidos - en el peine y sobre el peinador - se recogen para su contaje posterior. La bibliografía recoge que en el cuero cabelludo humano se desprenden a diario entre 30 y 100 cabellos de media (en función de la cantidad de cabello). En consecuencia, valores superiores a los anteriores se deben considerar anómalos y, por tanto, indicativos de un proceso de pérdida de cabello. De igual manera, se determina el número de cabellos que se desprenden durante el lavado del cabello (test "washing") en condiciones estandarizadas. Se pretende que, tras el tratamiento con la composición descrita en la presente invención, el número de cabellos desprendidos durante el peinado sea inferior al inicial. Para ello se lava el cuero cabelludo de cada voluntario y los cabellos desprendidos, tanto del agua del lavado como de su manipulación, se recogen para su recuento posterior.The number of hairs determined is determined detached during hair styling in conditions standardized (test "combing"). It is intended that, after treatment with the composition described in the present invention, the number of hair detached during styling is less than initial. For this, the tests are carried out at the beginning (T0), in the middle (T90) and at the end of the study (T180). As a precondition, the volunteers come to control without having washed their hair at least in the previous 48 hours and without having combed the hair in the 24 hours above, in order to keep the hair that are near the end of the telogen phase and avoid reduction Artificial percentage of hairs in telogen phase. After combing 30 Sometimes the scalp of each volunteer, the hair detached - in the comb and on the comb - are collected for post count. The bibliography shows that in the scalp human shed every day between 30 and 100 hair on average (in function of the amount of hair). Consequently, values higher than the previous ones should be considered anomalous and, for Thus, indicative of a hair loss process. Likewise way, the number of hairs detached during washing hair (test "washing") in conditions Standardized It is intended that, after treatment with the composition described in the present invention, the number of hairs detached during styling is less than the initial. For it each volunteer's scalp and hair is washed detached, both from the wash water and its handling, collect for later count.
Las fotografías obtenidas a partir de las grabaciones con microcámara a 70 aumentos del cuero cabelludo proporcionan una valiosa información sobre la regeneración de cabello. La comparación de las microfotografías de la misma área del cuero cabelludo al inicio (T0) y al final (T180) del estudio permite conocer si ha habido regeneración de cabello, mayor cantidad y/o grosor. En la Figura 1 se muestran tres imágenes de microcámaras que representan los mejores resultados obtenidos, que coinciden con los resultados del tricograma. En los tres voluntarios seleccionados se observa mayor cantidad de cabellos al final del tratamiento, es decir, hay mayor densidad capilar. Así mismo, muestran cabellos más gruesos y más pigmentados.The photographs obtained from the recordings with microcamera at 70 magnification of the scalp provide valuable information on the regeneration of hair. The comparison of the microphotographs of the same area of the scalp at the beginning (T0) and at the end (T180) of the study allows know if there has been hair regeneration, greater quantity and / or thickness. Figure 1 shows three images of micro cameras that they represent the best results obtained, which coincide with the Tricogram results. In the three selected volunteers, observe more hair at the end of the treatment, it is say, there is higher capillary density. They also show more hair thick and more pigmented.
Los resultados del tricograma al final del estudio (T180) mostrados en la figura 2 muestran que el 100% de los voluntarios han experimentado un aumento del número de cabellos en fase de crecimiento (fase anágena) al cabo de 6 meses de aplicación de la composición de la invención; además 12 de los 25 voluntarios supera el 15% de incremento de fase anágena o de crecimiento, superando uno de ellos el 25% de incremento.The results of the tricogram at the end of study (T180) shown in figure 2 show that 100% of the volunteers have experienced an increase in the number of hairs in growth phase (anagen phase) after 6 months of application of the composition of the invention; also 12 of the 25 volunteers exceeds 15% increase in anagen phase or growth, one of them exceeding the 25% increase.
En la figura 3 se muestran los resultados de estos ensayos. Tras 90 días de tratamiento, un 68% de los voluntarios experimentan una reducción de cabellos desprendidos por peinado respecto a T0. Tras 180 días de tratamiento el 92% de los voluntarios experimentan una reducción del número de cabellos desprendidos por peinado. Igualmente, en el ensayo de lavado, tras 90 días de tratamiento el 84% de los voluntarios experimentan una reducción del número de cabellos desprendidos respecto al momento inicial y, tras 180 días, el 92% experimentan una reducción del número de cabellos desprendidos por lavado.The results of these essays. After 90 days of treatment, 68% of volunteers experience a reduction of hair detached by hairstyle compared to T0. After 180 days of treatment 92% of volunteers experience a reduction in the number of hairs detached by hairstyle. Likewise, in the wash test, after 90 days of treatment 84% of volunteers experience a reduction in the number of hair detached from the moment initial and, after 180 days, 92% experience a reduction in number of hair detached by washing.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201031963A ES2354103B1 (en) | 2010-12-27 | 2010-12-27 | COMPOSITION CAPILLARY ACTIVATOR OF THE SIRTUINS AND USE OF THE SAME. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201031963A ES2354103B1 (en) | 2010-12-27 | 2010-12-27 | COMPOSITION CAPILLARY ACTIVATOR OF THE SIRTUINS AND USE OF THE SAME. |
Publications (3)
Publication Number | Publication Date |
---|---|
ES2354103A1 true ES2354103A1 (en) | 2011-03-10 |
ES2354103A9 ES2354103A9 (en) | 2011-04-28 |
ES2354103B1 ES2354103B1 (en) | 2011-12-05 |
Family
ID=43617141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201031963A Active ES2354103B1 (en) | 2010-12-27 | 2010-12-27 | COMPOSITION CAPILLARY ACTIVATOR OF THE SIRTUINS AND USE OF THE SAME. |
Country Status (1)
Country | Link |
---|---|
ES (1) | ES2354103B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3030248A1 (en) * | 2014-12-22 | 2016-06-24 | Oreal | PYRIDINE-DICARBOXYLIC ACID DERIVATIVE ASSOCIATION / PARTICULAR ANTIOXIDANT AGENT |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003013561A1 (en) * | 2001-08-07 | 2003-02-20 | Indena S.P.A. | Oral compositions for the treatment of scalp disorders |
WO2005084621A1 (en) * | 2004-03-02 | 2005-09-15 | Giuliani S.P.A. | Composition for regulating the trophism of hair follicles and the cutaneous production of sebum and use thereof in androgenetic alopecia |
FR2903309A1 (en) * | 2006-07-07 | 2008-01-11 | Labo Dermatologiques D Uriage | Compositions for combating hair loss comprise N-acetyl cysteine, cysteine, methionine, S-adenosyl methionine or N-acetyl methionylarginine ether ester, resveratrol, viniferin or grapevine extract, and arginine or lysine, |
ES2316312A1 (en) * | 2008-06-20 | 2009-04-01 | Ignacio Umbert Millet | Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same |
-
2010
- 2010-12-27 ES ES201031963A patent/ES2354103B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003013561A1 (en) * | 2001-08-07 | 2003-02-20 | Indena S.P.A. | Oral compositions for the treatment of scalp disorders |
WO2005084621A1 (en) * | 2004-03-02 | 2005-09-15 | Giuliani S.P.A. | Composition for regulating the trophism of hair follicles and the cutaneous production of sebum and use thereof in androgenetic alopecia |
FR2903309A1 (en) * | 2006-07-07 | 2008-01-11 | Labo Dermatologiques D Uriage | Compositions for combating hair loss comprise N-acetyl cysteine, cysteine, methionine, S-adenosyl methionine or N-acetyl methionylarginine ether ester, resveratrol, viniferin or grapevine extract, and arginine or lysine, |
ES2316312A1 (en) * | 2008-06-20 | 2009-04-01 | Ignacio Umbert Millet | Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3030248A1 (en) * | 2014-12-22 | 2016-06-24 | Oreal | PYRIDINE-DICARBOXYLIC ACID DERIVATIVE ASSOCIATION / PARTICULAR ANTIOXIDANT AGENT |
WO2016102489A1 (en) * | 2014-12-22 | 2016-06-30 | L'oreal | Particular pyridinedicarboxylic acid derivative/antioxidant combination |
CN107106452A (en) * | 2014-12-22 | 2017-08-29 | 欧莱雅 | Specific pyridinedicarboxylicacid acid derivatives/antioxidant combination |
US20180000712A1 (en) * | 2014-12-22 | 2018-01-04 | L'oreal | Particular pyridinedicarboxylic acid derivative/antioxidant combination |
CN107106452B (en) * | 2014-12-22 | 2020-11-06 | 欧莱雅 | Specific dipicolinic acid derivative/antioxidant combinations |
US10835468B2 (en) * | 2014-12-22 | 2020-11-17 | L'oreal | Particular pyridinedicarboxylic acid derivative/antioxidant combination |
Also Published As
Publication number | Publication date |
---|---|
ES2354103B1 (en) | 2011-12-05 |
ES2354103A9 (en) | 2011-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2407513C2 (en) | Agent containing l-carnitine or l-carnitine derivatives and at least one other certain substance | |
ES2645243T3 (en) | Compositions and methods to stimulate MAGP-1 and improve skin appearance | |
JP2006117700A (en) | Use of extract of at least one vaccinium-type plant as anti-glycation agent | |
ES2769268T3 (en) | Synergistic extract of Palmaria palmata | |
ES2863307T3 (en) | Topical composition comprising plant extracts | |
ES2929480T3 (en) | Compositions containing plant mucilage | |
ES2743205T3 (en) | Cosmetic compositions containing an Arctic blackberry cell culture preparation | |
JP2020529420A (en) | New cosmetic use of Nepherium rappaceum extract | |
Lanjewar et al. | Review on Hair Problem and its Solution | |
KR101503420B1 (en) | Cosmetic composition for anti-aging of the skin | |
WO2017035766A1 (en) | Hair cleansing composition containing lotus flower oil and use thereof | |
CA2826235A1 (en) | New use of compositions for preventing chemotherapy and radiotherapy induced alopecia (cria), reducing cria impact and improving the appearance of hair re-growth after cria | |
KR101476004B1 (en) | Cosmetic composition containing onion skin extracts and loquat leaf extracts for the acceleration of hair growth | |
ES2354103B1 (en) | COMPOSITION CAPILLARY ACTIVATOR OF THE SIRTUINS AND USE OF THE SAME. | |
US11648196B2 (en) | Active ingredient including a black oat extract and a spiny restharrow extract and cosmetic uses, in particular anti-graying | |
JP5026205B2 (en) | Hair composition | |
WO2014167557A1 (en) | Cosmetic topical skin treatment formulation | |
Kumar et al. | Physiology and anatomy of hair in drug abusing cases | |
KR102212894B1 (en) | Cosmetic Composition For Promoting Hair Volume Containing Walnut Peptides As Active Ingredient | |
Kilala Tilaar et al. | Safety and efficacy evaluation on combination of Lansium domesticum fruit extract and Hibiscus rosa-sinensis flower extract as lightening agent for cosmetic | |
RU2170570C1 (en) | Composition for hair washing | |
JP6782085B2 (en) | Whitening inhibitor, cell death inhibitor, active oxygen generation inhibitor, DNA damage inhibitor, mitochondrial damage inhibitor | |
KR20220114895A (en) | Hair conditioning composition comprising of butanol fraction of juglans sinensis ethanol extract | |
ES2908663T3 (en) | A cosmetic composition, method and process of applying the same. | |
US20220331223A1 (en) | Hair treatment compositions and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2354103 Country of ref document: ES Kind code of ref document: B1 Effective date: 20111205 |